Compare ACADIA Pharmaceuticals Inc. (ACAD) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs PubMatic Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while PubMatic Inc trades at $17.16 (market cap $804.41M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 6.3× PubMatic Inc's market cap. Which is the better fit depends on your goals.
| ACAD | PUBM | |
|---|---|---|
Market Cap | $5.07B | $804.41M |
Sector | Health | Technology |
52-Week High | $29.41 | $17.78 |
52-Week Low | $20.06 | $6.28 |
Enterprise Value | $4.19B | $707.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
PubMatic (PUBM) trades at $17.76, down slightly by 0.11% today. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Recent Q2 2026 earnings beat expectations with 10.5% revenue growth and a significant EPS surprise. The company is focusing on high-margin segments like mobile app and CTV advertising, supported by new AI product launches and executive appointments.
The outlook is cautiously optimistic with a consensus price target of $20.83, implying 17% upside. However, risks include persistent net losses, a high P/E ratio of 132, and competitive pressures in digital advertising. Analyst sentiment is split evenly between Buy and Hold ratings, reflecting uncertainty around near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
